Our preliminary sero-epidemiologic survey of ethnic groups in Israel has shown that 37% of healthy Falasha individuals (""""""""Black Jews"""""""" of Ethopian decent) have antibodies for HTLV-I and -II.* This is the highest known prevalence of antibody to HTLV in any population and indicates widespread infection with HTLV. HTLV is an exogenous virus and is associated with the development of several human malignancies. Sero-epidemiologic studies will be performed to (i) characterize the clinically relevant biologic activities; (ii) detect the exact mode of horizontal transmission of the virus; (iii) study virus-host interactions including determinations of host-range and localization and overlap of different types of HTLV. The hypothesis will be tested that prevalence of HTLV antibodies is correlated with antibodies to other viruses implicated in human malignancy, specifically CMV, EBV, and HBV. A cross-sectional study will be done to confirm the hypothesis that HTLV antibodies are associated with specific T-cell malignancy, and to probe for new and unrecognized disease associations. Prospective studies will test the mode of HTLV transmission of mother to child and will characterize the immune response of neonatal HTLV infection. Absorption enzyme immunoassay studies suggest that sero-positive Falashas carry a new subtype of HTLV that crossreacts with HTLV types I and II but differs from them. HTLV will be isolated from the lymphocytes of seropositive Falasha individuals, grown in culture, and purified in quantity. An ELISA test will be established and competition immunoassays among HTLV types -I, -II, and -Falasha will be performed. HTLV isolated from Falasha individuals will be molelcularly cloned, restriction maps will be derived, and selected regions of the viral genome will be sequenced and compared with other subtypes of the group. * In addition, 10% of these have antibodies to HTLV-III as well.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Research Project (R01)
Project #
1R01CA042432-01
Application #
3183736
Study Section
Epidemiology and Disease Control Subcommittee 3 (EDC)
Project Start
1986-09-30
Project End
1988-08-31
Budget Start
1986-09-30
Budget End
1987-08-31
Support Year
1
Fiscal Year
1986
Total Cost
Indirect Cost
Name
University of California San Diego
Department
Type
Schools of Medicine
DUNS #
077758407
City
La Jolla
State
CA
Country
United States
Zip Code
92093